Display options
Cite
Nakamuta M, Kotoh K, Enjoji M, et al. Effects of lamivudine on serum albumin levels correlate with pretreatment HBV-DNA levels in cirrhotic patients. Comp Hepatol. 2007;6:3doi: 10.1186/1476-5926-6-3.
Nakamuta, M., Kotoh, K., Enjoji, M., Kajiwara, E., Shimono, J., Masumoto, A., Maruyama, T., Furusyo, N., Nomura, H., Sakai, H., Takahashi, K., Azuma, K., Shimoda, S., Tanabe, Y., & Hayashi, J. (2007). Effects of lamivudine on serum albumin levels correlate with pretreatment HBV-DNA levels in cirrhotic patients. Comparative hepatology, 63. https://doi.org/10.1186/1476-5926-6-3
Nakamuta, Makoto, et al. "Effects of lamivudine on serum albumin levels correlate with pretreatment HBV-DNA levels in cirrhotic patients." Comparative hepatology vol. 6 (2007): 3. doi: https://doi.org/10.1186/1476-5926-6-3
Nakamuta M, Kotoh K, Enjoji M, Kajiwara E, Shimono J, Masumoto A, Maruyama T, Furusyo N, Nomura H, Sakai H, Takahashi K, Azuma K, Shimoda S, Tanabe Y, Hayashi J. Effects of lamivudine on serum albumin levels correlate with pretreatment HBV-DNA levels in cirrhotic patients. Comp Hepatol. 2007 May 01;6:3. doi: 10.1186/1476-5926-6-3. PMID: 17470300; PMCID: PMC1884174.
Copy Download .nbib Format: NLM
Share it on

Comp Hepatol. 2007 May 01;6:3. doi: 10.1186/1476-5926-6-3.

Effects of lamivudine on serum albumin levels correlate with pretreatment HBV-DNA levels in cirrhotic patients.

Comparative hepatology

Makoto Nakamuta, Kazuhiro Kotoh, Munechika Enjoji, Eiji Kajiwara, Junya Shimono, Akihide Masumoto, Toshihiro Maruyama, Norihiro Furusyo, Hideyuki Nomura, Hironori Sakai, Kazuhiro Takahashi, Koichi Azuma, Shinji Shimoda, Yuichi Tanabe, Jun Hayashi

Affiliations

  1. Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Japan. [email protected]

PMID: 17470300 PMCID: PMC1884174 DOI: 10.1186/1476-5926-6-3

Abstract

BACKGROUND: Lamivudine treatment has been recently demonstrated to increase the serum albumin levels in cirrhotic patients with hepatitis B virus (HBV) infection, but the precise mechanism remains unclear. We hypothesized that the improvement of hypoalbuminemia by lamivudine may be attributable to the reduction of HBV replication itself, rather than to cessation of hepatitis. In order to confirm this hypothesis, in this study we evaluated factors which correlated with the increase in serum albumin levels. Fifty-four patients (Child-Pugh A/B/C, 35/9/10) with HBV-related liver cirrhosis who had been treated with lamivudine for more than 12 months were evaluated. We analyzed the correlation between the increase in serum albumin levels at month 12 after starting treatment (Delta-albumin) and various pretreatment variables. We also analyzed the correlation between Delta-albumin and the reduction in serum levels of HBV-DNA (Delta-HBV-DNA) or alanine aminotransferase (Delta-ALT) at month 12.

RESULTS: The average Delta-albumin was 0.38 g/dL and only serum HBV-DNA levels before treatment correlated significantly with Delta-albumin. We also analyzed the correlation in patients whose alanine aminotransferase levels were normalized after 12 months so that the possible influence of breakthrough hepatitis could be excluded. Even among this subgroup of patients, there was no significant correlation between Delta-albumin and either pretreatment alanine aminotransferase levels or Delta-ALT. In contrast, in patients whose serum HBV-DNA was undetectable at month 12, we found a significant correlation between Delta-albumin and both pretreatment serum HBV-DNA levels and Delta-HBV-DNA.

CONCLUSION: Our results demonstrated that albumin levels are associated with pretreatment HBV-DNA but not with alanine aminotransferase levels.

References

  1. World J Gastroenterol. 2004 Jun 1;10(11):1686-7 - PubMed
  2. J Viral Hepat. 2005 Jul;12(4):357-63 - PubMed
  3. Clin Invest Med. 2003 Feb;26(1):27-34 - PubMed
  4. J Hepatol. 2000 Aug;33(2):308-12 - PubMed
  5. Ann Hepatol. 2002 Apr-Jun;1(2):72-9 - PubMed
  6. J Gastroenterol Hepatol. 2002 Nov;17(11):1198-204 - PubMed
  7. N Engl J Med. 2004 Mar 11;350(11):1118-29 - PubMed
  8. Biochim Biophys Acta. 2000 Jan 31;1490(1-2):63-73 - PubMed
  9. Hepatol Res. 2005 Jan;31(1):13-17 - PubMed
  10. World J Gastroenterol. 2005 Mar 7;11(9):1356-60 - PubMed
  11. Lancet. 2003 Dec 20;362(9401):2089-94 - PubMed
  12. Hepatology. 2000 Oct;32(4 Pt 1):847-51 - PubMed
  13. J Gastroenterol. 2004 Nov;39(11):1078-84 - PubMed
  14. Z Gastroenterol. 2004 Jan;42(1):15-8 - PubMed
  15. Hepatology. 2001 Aug;34(2):411-6 - PubMed
  16. J Hepatol. 1991 Mar;12(2):246-50 - PubMed
  17. Liver Int. 2005 Apr;25(2):220-5 - PubMed
  18. J Hepatol. 2000 Aug;33(2):301-7 - PubMed
  19. World J Gastroenterol. 2001 Aug;7(4):445-54 - PubMed
  20. Hepatology. 2000 Jan;31(1):207-10 - PubMed
  21. Gut. 2002 Oct;51(4):597-9 - PubMed
  22. Infez Med. 1997 Jul;5(3):168-73 - PubMed
  23. J Virol. 1994 Sep;68(9):5792-803 - PubMed
  24. J Viral Hepat. 2005 Jul;12(4):386-92 - PubMed
  25. Scand J Gastroenterol. 2002 Mar;37(3):366-9 - PubMed
  26. Liver Transpl. 2000 Nov;6(6):715-20 - PubMed
  27. Am J Gastroenterol. 2001 Jan;96(1):265 - PubMed
  28. Transplantation. 2002 Oct 27;74(8):1119-24 - PubMed
  29. J Virol. 1994 Dec;68(12):8321-30 - PubMed
  30. Hepatol Res. 2001 Oct;21(2):159-168 - PubMed
  31. Hepatogastroenterology. 2003 Dec;50 Suppl 2:ccxcv-ccxcvii - PubMed
  32. Am J Gastroenterol. 2002 Apr;97(4):1003-9 - PubMed
  33. Hepatology. 2000 Nov;32(5):1154-62 - PubMed
  34. Intern Med. 2002 Oct;41(10):774-9 - PubMed
  35. Hepatology. 2001 Feb;33(2):424-32 - PubMed
  36. Dig Dis Sci. 2004 Feb;49(2):300-3 - PubMed
  37. Semin Liver Dis. 2004;24 Suppl 1:37-44 - PubMed

Publication Types